GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Major stock indexes closed lower on Friday, after the week saw a flurry of events, including DeepSeek scare and earnings ...

The US Food and Drug Administration (FDA) has approved ... Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics.

The FDA has granted ... people with chronic kidney disease (CKD). The new indication could unlock a sizeable new market for Jardiance (empagliflozin), which is already approved to control blood ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

This drug is also used as a treatment option to prevent worsening chronic kidney disease (CKD) and is also used to reduce ... a drug to treat a condition for which the drug was not FDA-approved ...

non-alcohol fatty liver disease (NAFLD), and other chronic diseases. There are currently 12 GLP-1 agonists approved for use by the U.S. Food and Drug Administration (FDA): Victoza is approved for use ...